Episode Details
Back to Episodes
Your Eye Pressure May Look Fine at the Doctor — While Hidden Spikes at Home Still Drive Glaucoma Progression
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/your-eye-pressure-may-look-fine-at-the-doctor-while-hidden-spikes-at-home-still-drive-glaucoma-progression
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Your Eye Pressure May Look Fine at the Doctor—While Hidden Spikes at Home Still Drive Glaucoma Progression Yes: a reassuring pressure reading in the clinic can miss pressure changes that happen during the rest of the day. A study published online on September 30, 2026, found that two new measures of pressure above a patient’s own target were associated with faster visual-field decline when calculated from home readings—but not from office readings. The result is important, but it does not prove that pressure spikes caused the damage, or that home monitoring prevents it. () The key idea is simple: glaucoma care may learn more from a pattern of pressure readings than from one reading at an appointment. But today’s home devices take occasional readings, not continuous measurements, and the study’s “pressure burden” measures are still early research tools. What the September 30, 2026 study found The study, “In-office and remote intraocular pressure metrics associated with visual field progression in treated open-angle glaucoma,” compared pressure measurements taken at home with measurements recorded during routine clinic care. It asked whether different ways of summarizing pressure were associated with how quickly visual-field test results changed over time. () Its most notable finding was that average pressure and maximum pressure were not significantly associated with visual-field decline in this sample—whether measured at home or in the clinic. However, two measures that considered pressure relative to each patient’s individual treatment target—average and total excess above that target—were associated with faster decline in home readings. That distinction matters. This was a retrospective association study, not a trial that assigned patients to home monitoring or showed that reducing pressure burden prevents progression. The study can identify a signal worth investigating; it cannot establish cause and effect. Reconstructing the study population and measurements The researchers reviewed records from 397 treated patients with 777 eyes at Johns Hopkins University and the University of Utah. The final analysis included 94 patients and 150 eyes after exclusions. Patients had used an iCare HOME rebound tonometer between October 2018 and September 2024. The analysis focused on patients with open-angle glaucoma and excluded several other glaucoma types, including angle-closure, traumatic, and uveitic glaucoma. () Who was included? For the full table, please open this article on visualfieldtest.com. The mean visual-field result indicates a wide spread of glaucoma severity, not one uniform stage. The paper does not report how many eyes fell into each stage, so the average cannot be used to reconstruct those percentages. () What treatment were patients receiving? All participants were treated for glaucoma, and the researchers restricted the clinical record data to periods when treatment was consistent with the home-measurement period. Most patients were using at least one pressure-lowering eye drop. Before the home-monitoring period, many eyes had also undergone procedures, including cataract surgery, selective laser trabeculoplasty, trabeculectomy, or micro-invasive glaucoma surgery. These procedure categories can overlap. () Each patient’s target pres